Archive

Dive into a collection of past posts and rediscover timeless content.

The Medical Technology Giant Where the Legal Clouds Are Lifting and the Earnings Multiple Hasn’t Caught Up

A completed biosciences spin-off, and a forward multiple that looks cheap against the peer group make this one of the more interesting setups in healthcare right now.

Sep 22, 2026

Undervalued Edge

This Cancer Company Already Sells One Approved Drug That Pays for Everything Else

A cancer trial worked in most patients and fell short in one smaller group. That nuance got flattened into a single ugly day of selling.

Sep 21, 2026

Undervalued Edge Analysis

This Biotech Has $700 Million in Revenue and Another Commercial Opportunity Approaching

Three approved medicines, a near-term Phase 3 readout, and an FDA decision eight days away make this one of the busiest catalyst windows in biotech right now.

Sep 19, 2026

Undervalued Edge

This Newly Public Travel Software Company Gave Wall Street a 30% Growth Target

This travel software stock grew revenue 38% and cut its loss nearly in half. Now management expects another 30% growth quarter.

Sep 18, 2026

Undervalued Edge Analysis

The World’s Largest RV Maker Is Near a 52-Week Low With Earnings Five Days Away and a Cost Restructuring Already Running

Leadership consolidation aimed at driving out costs, plus a consensus pointing to an earnings recovery, make this one worth understanding before the next print.

Sep 17, 2026

Undervalued Edge

A Buyer Agreed to Pay Nearly Twice as Much for This Stock, but Shares Still Trade Below That Price

When a takeout gets announced at double the price, the gap usually vanishes within days. This one has not entirely. See why that remaining sliver is worth a look.

Sep 16, 2026

Undervalued Edge Analysis

The Discount Retailer With Six Straight Positive Comp Quarters and a Q3 Catalyst Coming in December

The founding-era operator is back, comps have flipped positive for six straight quarters, and a $700 million buyback is starting in the back half of this year.

Sep 15, 2026

Undervalued Edge

This Company Has Been Hiding Better Cash Flow Behind Two Years of Ugly Accounting

Revenue has taken a hit from a major business transition, but recurring cash flow has been moving in the opposite direction. The next few quarters could expose the gap.

Sep 14, 2026

Undervalued Edge Analysis

The Healthcare Spinoff Getting a Second Act Through Portfolio Surgery

A massive Q2 earnings beat, and a forward earnings multiple below the peer group average make this 3M carveout worth understanding before the next catalyst hits.

Sep 12, 2026